These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31765705)

  • 1. Using in vitro lipolysis and SPECT/CT in vivo imaging to understand oral absorption of fenofibrate from lipid-based drug delivery systems.
    Tran T; Bønløkke P; Rodríguez-Rodríguez C; Nosrati Z; Esquinas PL; Borkar N; Plum J; Strindberg S; Karagiozov S; Rades T; Müllertz A; Saatchi K; Häfeli UO
    J Control Release; 2020 Jan; 317():375-384. PubMed ID: 31765705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) Containing Rice Bran Oil for Enhanced Fenofibrate Oral Delivery: In Vitro Digestion, Ex Vivo Permeability, and In Vivo Bioavailability Studies.
    Karavasili C; Andreadis II; Tsantarliotou MP; Taitzoglou IA; Chatzopoulou P; Katsantonis D; Zacharis CK; Markopoulou C; Fatouros DG
    AAPS PharmSciTech; 2020 Jul; 21(6):208. PubMed ID: 32725343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.
    Mohsin K; Alamri R; Ahmad A; Raish M; Alanazi FK; Hussain MD
    Int J Nanomedicine; 2016; 11():2829-38. PubMed ID: 27366063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo performance of monoacyl phospholipid-based self-emulsifying drug delivery systems.
    Tran T; Siqueira SDVS; Amenitsch H; Müllertz A; Rades T
    J Control Release; 2017 Jun; 255():45-53. PubMed ID: 28365295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
    Borkar N; Xia D; Holm R; Gan Y; Müllertz A; Yang M; Mu H
    Eur J Pharm Sci; 2014 Jan; 51():204-10. PubMed ID: 24134899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS).
    Thomas N; Holm R; Müllertz A; Rades T
    J Control Release; 2012 May; 160(1):25-32. PubMed ID: 22405903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate oral absorption from SNEDDS and super-SNEDDS is not significantly affected by lipase inhibition in rats.
    Michaelsen MH; Siqueira Jørgensen SD; Abdi IM; Wasan KM; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2019 Sep; 142():258-264. PubMed ID: 31276759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems.
    Tran T; Siqueira SDVS; Amenitsch H; Rades T; Müllertz A
    Eur J Pharm Sci; 2017 Oct; 108():62-70. PubMed ID: 27890596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Precipitation of Poorly Soluble Drugs from Lipid-Based Drug Delivery Systems.
    Sassene PJ; Michaelsen MH; Mosgaard MD; Jensen MK; Van Den Broek E; Wasan KM; Mu H; Rades T; Müllertz A
    Mol Pharm; 2016 Oct; 13(10):3417-3426. PubMed ID: 27533712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of in vitro Fick's first law, lipolysis, and in vivo rat models for oral absorption on BCS II drugs in SNEDDS.
    Ye J; Wu H; Huang C; Lin W; Zhang C; Huang B; Lu B; Xu H; Li X; Long X
    Int J Nanomedicine; 2019; 14():5623-5636. PubMed ID: 31440045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ability of two in vitro lipolysis models reflecting the human and rat gastro-intestinal conditions to predict the in vivo performance of SNEDDS dosing regimens.
    Siqueira Jørgensen SD; Al Sawaf M; Graeser K; Mu H; Müllertz A; Rades T
    Eur J Pharm Biopharm; 2018 Mar; 124():116-124. PubMed ID: 29288805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
    Dening TJ; Rao S; Thomas N; Prestidge CA
    Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Alternative Lipid Excipients in the Design of Self-Nanoemulsifying Formulations for Fenofibrate: Characterization,
    Alshamsan A; Kazi M; Badran MM; Alanazi FK
    Front Pharmacol; 2018; 9():1219. PubMed ID: 30455642
    [No Abstract]   [Full Text] [Related]  

  • 14. Combining lipid based drug delivery and amorphous solid dispersions for improved oral drug absorption of a poorly water-soluble drug.
    Nora GI; Venkatasubramanian R; Strindberg S; Siqueira-Jørgensen SD; Pagano L; Romanski FS; Swarnakar NK; Rades T; Müllertz A
    J Control Release; 2022 Sep; 349():206-212. PubMed ID: 35787914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS).
    Michaelsen MH; Wasan KM; Sivak O; Müllertz A; Rades T
    AAPS J; 2016 Jan; 18(1):180-6. PubMed ID: 26486790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate.
    Thomas N; Richter K; Pedersen TB; Holm R; Müllertz A; Rades T
    AAPS J; 2014 May; 16(3):539-49. PubMed ID: 24687210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Oral Absorption of fenofibrate in Lipid-Based Drug Delivery Systems by Combining In Vitro Lipolysis with the Mucus-PVPA Permeability Model.
    Falavigna M; Klitgaard M; Berthelsen R; Müllertz A; Flaten GE
    J Pharm Sci; 2021 Jan; 110(1):208-216. PubMed ID: 32916137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.
    Mohsin K
    AAPS PharmSciTech; 2012 Jun; 13(2):637-46. PubMed ID: 22547370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats.
    Berthelsen R; Holm R; Jacobsen J; Kristensen J; Abrahamsson B; Müllertz A
    Mol Pharm; 2015 Apr; 12(4):1062-71. PubMed ID: 25679417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.